Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 67% Improvement Relative Risk ICU admission -6% HCQ  Ramírez-García et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 403 patients in Spain Lower mortality with HCQ (p=0.0000062) c19hcq.org Ramírez-García et al., Archivos de Med.., May 2021 Favors HCQ Favors control

Hydroxychloroquine and Tocilizumab in the Treatment of COVID-19: A Longitudinal Observational Study

Ramírez-García et al., Archivos de Medicina Universitaria
May 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments. c19hcq.org
Retrospective 403 hospitalized patients in Spain, showing lower mortality with treatment, however authors do not adjust for the differences between the groups. Confounding by indication is likely.
This study is excluded in the after exclusion results of meta analysis: excessive unadjusted differences between groups; substantial unadjusted confounding by indication likely.
risk of death, 67.0% lower, RR 0.33, p < 0.001, treatment 48 of 350 (13.7%), control 22 of 53 (41.5%), NNT 3.6.
risk of ICU admission, 6.0% higher, RR 1.06, p = 1.00, treatment 35 of 350 (10.0%), control 5 of 53 (9.4%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ramírez-García et al., 31 May 2021, retrospective, Spain, peer-reviewed, 5 authors.
This PaperHCQAll
Hydroxychloroquine and Tocilizumab in the Treatment of COVID-19: A Longitudinal Observational Study
Asensi -Gómez, ; Carbajo-García, ; Cobano-Jiménez, Juan Luis, ; Lenker-Andrade, ; Vázquez- Delgado, ; Vivas-Del-Torno, ; García-Molina, ; Flor-Cremades, María Consuelo, ; Muñoz-Rojas, ; Moleón-Moya
Objectives The objective of this study is to evaluate the use of hydroxychloroquine and tocilizumab at the beginning of the COVID-19 pandemic and to describe the profile of patients who received these treatments. Method The medical records of 403 patients admitted for COVID-19 from March 1 to April 15, 2020 at the San Cecilio University Hospital (Granada, Spain) were analyzed. The data collected included sex, age, days hospitalized, previous pathologies and/or treatments, possible outcomes and drugs administered at the hospital. Student's t-test and Pearson's chi-square tests were used as statistical parameters to estimate the possible associations between the defined variables. Results Patients with a mean age of 66 years (standard deviation = 15.38), were hospitalized for an average of 15 days (standard deviation = 12.89). The ICU admission rate was 9.93 %, and the death rate added up to 17.37 % of the total number of patients. During the first wave of the pandemic, hydroxychloroquine was administered to the majority of hospitalized patients, while tocilizumab was restricted to the more severe cases. Conclusions The results showed two distinct trends in the use of the drugs studied. Tocilizumab was administered to a small number of patients, mainly those with longer length of stay or with complications. Hydroxychloroquine was administered independently of the initial characteristics of patients, especially those who presented comorbidities or took multiple medications.
Conflicts of interest The authors of this paper declare no conflicts of interest.
References
Arcos, Puche, Vera, Controversy regarding ACE inhibitors/ARBs in Covid-19, Rev Esp Cardiol (Engl Ed)
Awadasseid, Wu, Tanaka, Zhang, Initial success in the identification and management of the coronavirus disease 2019 (COVID-19) indicates human-to-human transmission in Wuhan, China, Int J Biol Sci
Bansal, Goyal, Cusick, Lahan, Dhaliwal et al., Hydroxychloroquine: A comprehensive review and its controversial role in coronavirus disease 2019, Ann Med
Campochiaro, Della-Torre, Cavalli, Luca, Ripa et al., Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study, Eur J Intern Med
Capra, Rossi, Mattioli, Romanelli, Scarpazza et al., Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia, Eur J Intern Med
Cheong, Bartell, Peeraphatdit, Mosli, Gastrointestinal and liver manifestations of COVID-19. Saudi J Gastroenterol Off, J Saudi Gastroenterol Assoc
Colaneri, Bogliolo, Valsecchi, Sacchi, Zuccaro et al., Tocilizumab for treatment of severe COVID-19 patients: preliminary results from SMAtteo COvid19 REgistry (SMACORE), Microorganisms
De Brouwer, Van Veldhuisen, De Boer, Surviving the first COVID-19 wave and learning lessons for the second, Eur J Heart Fail
Dubert, Visseaux, Isernia, Bouadma, Deconinck et al., Case report study of the first five COVID-19 patients treated with remdesivir in France, Int J Infect Dis
Fontana, Alfano, Mori, Amurri, Tei et al., Covid-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine, Am J Transplant
Fravel, Ernst, Drug Interactions with Antihypertensives, Curr Hypertens Rep
Gallego, Codorniu, Cabrero, The impact of COVID-19 on the elderly dependent population in Spain with special reference to the residential care sector, Ciência & Saúde Coletiva
Gautret, Lagier, Parola, Meddeb, Mailhe et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Gupta, Wang, Hayek, Chan, Mathews et al., Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19, JAMA Intern Med
Gutiérrez-Abejón, Tamayo, Garcia, Álvarez, Herrera-Gómez, Clinical Profile, Treatment and Predictors during the First COVID-19 Wave: A Population-Based Registry Analysis from Castile and Leon Hospitals, Int J Environ Res Public Health
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Ibáñez, Martinez, Valenzuela, Silva, Valenzuela, Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?, Clin Rheumatol
Klopfenstein, Zayet, Lohse, Balblanc, Badie et al., Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients, Med Mal Infect
Lemmon, Chapman, Malcolm, Kelley, Shaw et al., Beyond the First Wave: Consequences of COVID-19 on High-Risk Infants and Families, Am J Perinatol
Luo, Liu, Qiu, Liu, Liu et al., Tocilizumab treatment in COVID-19: a single center experience, J Med Virol
Miranda, Silva, Capita, Alonso-Calleja, Igrejas et al., Implications of antibiotics use during the COVID-19 pandemic: present and future, J Antimicrob Chemother
Pereira, Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review, J Toxicol Environ Heal Part B
Risch, Early outpatient treatment of symptomatic, high-risk COVID-19 patients that should be ramped up immediately as key to the pandemic crisis, Am J Epidemiol
Rubio, Castillo, De, De La Hera Fernández, Arrabal et al., Effectiveness of corticoid pulses in patients with cytokine storm syndrome induced by SARS-CoV-2 infection, Med Clínica (English Ed
Russell, Millar, Baillie, Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury, Lancet
Samaee, Mohsenzadegan, Ala, Maroufi, Moradimajd, Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease, Int Immunopharmacol
Schiffrin, Flack, Ito, Muntner, Webb, Hypertension and COVID-19
Sciascia, Aprà, Baffa, Baldovino, Boaro et al., Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in severe patients with COVID-19, Clin Exp Rheumatol
Stone, Frigault, Serling-Boyd, Fernandes, Harvey et al., Efficacy of tocilizumab in patients hospitalized with Covid-19, N Engl J Med
Xu, Han, Li, Sun, Wang et al., Effective treatment of severe COVID-19 patients with tocilizumab, Proc Natl Acad Sci
Zhou, Dai, Tong, COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression, J Antimicrob Chemother
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit